Related Experiment Video
Updated: Jul 18, 2025

Exploring the Arginine Methylome by Nuclear Magnetic Resonance Spectroscopy
Published on: December 16, 2021
Integrative Evaluation of the Clinical Significance Underlying Protein Arginine Methyltransferases in Hepatocellular
Yikun Jiang1, Shibo Wei2, Jin-Mo Koo3
1Department of Orthopedics, The Second Hospital of Jilin University, Changchun 130041, China.
Abstract:
HCC is a major contributor to cancer-related mortality worldwide. Curative treatments are available for a minority of patients diagnosed at early stages; however, only a few multikinase inhibitors are available and are marginally effective in advanced cases, highlighting the need for novel therapeutic targets. One potential target is the protein arginine methyltransferase, which catalyzes various forms of arginine methylation and is often overexpressed in various cancers. However, the diverse expression patterns and clinical values of PRMTs in HCC remain unclear. In the present study, we evaluated the transcriptional expression of PRMTs in HCC cohorts using publicly available datasets. Our results revealed a significant association between PRMTs and prognosis in HCC patients with diverse clinical characteristics and backgrounds. This highlights the promising potential of PRMTs as prognostic biomarkers in patients with HCC. In particular, single-cell RNA (scRNA) sequencing analysis coupled with another human cohort study highlighted the pivotal role of PRMT1 in HCC progression, particularly in the context of Tex. Translating these findings into specific therapeutic decisions may address the unmet therapeutic needs of patients with HCC.
Insights
Protein arginine methyltransferases (PRMTs) show significant associations with prognosis in hepatocellular carcinoma (HCC) patients. PRMT1 plays a pivotal role in HCC progression, offering potential as a novel therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally.
- Limited effective treatments exist for advanced HCC, necessitating new therapeutic targets.
- Protein arginine methyltransferases (PRMTs) are implicated in various cancers, but their role in HCC is unclear.
Purpose of the Study:
- To evaluate the expression patterns and clinical significance of PRMTs in HCC.
- To identify PRMTs as potential prognostic biomarkers for HCC.
- To investigate the specific role of PRMT1 in HCC progression.
Main Methods:
- Analysis of transcriptional expression of PRMTs in HCC patient cohorts using public datasets.
- Utilized single-cell RNA sequencing (scRNA) analysis.
- Correlated PRMT expression with clinical characteristics and patient prognosis.
Main Results:
- Significant associations were found between PRMT expression and prognosis in HCC patients.
- PRMTs demonstrate potential as prognostic biomarkers for HCC.
- PRMT1 was identified as a key player in HCC progression, especially in T-cell exhaustion (Tex) contexts.
Conclusions:
- PRMTs are promising prognostic biomarkers for hepatocellular carcinoma.
- PRMT1 plays a critical role in HCC progression and represents a potential therapeutic target.
- Findings may inform novel therapeutic strategies for advanced HCC patients.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Abnormal Proliferation

